News Releases

Leading New Gene-based Therapies

Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy


LOS ANGELES, March 24, 2021 (NASDAQ: ENOB) – Seraph Research Institute (SRI) and Enochia BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that a 36-year old patient with recurrent glioblastoma achieved complete remission for a period of 15 months. The important findings were published today,

Read more

Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

March 24, 2021


Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

February 22, 2021


Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

September 10, 2020


Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

July 27, 2020


Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

June 8, 2020


Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures

May 13, 2020


Enochian Biosciences Announces Scientific Presentations at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting

April 9, 2020


Enochian Biosciences Announces FDA INTERACT Meeting for a Potential Cure for HIV

February 24, 2020


Enochian Biosciences Acquires an Exclusive License for a Novel Hepatitis B Virus Potential Treatment or Cure

February 3, 2020


Enochian Biosciences, A Company Focused on Gene-Modified Cellular Therapy in Infectious Disease and Cancer, Announces the Appointment of Two Board Members

January 8, 2020


Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus

December 10, 2019


Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment

November 25, 2019